"Andexxa is a strategic fit with our existing portfolio of transformative medicines and is well-aligned with our demonstrated expertise in hematology, neurology and critical care."The deal makes a good fit for Alexion's critical care business, Chief Financial OfficerÂ Aradhana Sarin said in an interview.